Maintelyte (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Glucose, Sodium Acetate Trihydr)

The active ingredients—magnesium chloride, potassium chloride, sodium chloride, glucose, and sodium acetate—provide key electrolytes and a carbohydrate source directly into the bloodstream. They restore extracellular ion concentrations, support cellular metabolism, and act as a buffer to maintain acid‑base balance, thereby normalising fluid and electrolyte status.

The prescribed dose of Maintelyte is determined by the treating clinician based on the patient’s clinical condition, electrolyte levels, and volume status. Healthcare professionals calculate the appropriate volume and infusion rate to safely correct the identified deficits.

Safety data for Maintelyte in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the prescriber. The decision to administer the product to pregnant or nursing women rests with the treating physician.

To order Maintelyte, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Maintelyte offers a balanced combination of magnesium, potassium, sodium, glucose, and acetate, providing both electrolyte replacement and a metabolic buffer. Compared with simpler saline solutions, it addresses multiple electrolyte deficits in a single infusion, reducing the need for additional supplements and supporting more comprehensive fluid therapy.

Maintelyte should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Before use, inspect the container for any particulate matter or discoloration and allow the solution to reach room temperature if required for infusion.

Maintelyte is administered intravenously as a sterile solution for injection. The infusion rate is set by the prescriber and may be adjusted based on the patient’s hemodynamic status and electrolyte monitoring. Administration should be performed by qualified healthcare personnel using aseptic technique.

Serious risks include severe hyperkalemia or hypermagnesemia, which can cause cardiac arrhythmias, respiratory depression, or cardiac arrest. Anaphylactic reactions and fluid overload leading to pulmonary edema are also possible. Continuous monitoring of electrolytes and cardiac function is essential during therapy.

Maintelyte should be avoided in patients with known hypersensitivity to any component, existing severe hyperkalemia, uncontrolled cardiac arrhythmias, or those for whom rapid fluid expansion is contraindicated. Clinicians must evaluate individual patient factors before initiating therapy.